Special Issue

Engineered Nanoparticle Mediated Vaccine Development for Immunoprevention of Cancer

Message from the Guest Editors

Several nanoparticulate systems such as liposomes, polymers, micelles, virus like nanoparticles, and inorganic nanoparticles, to name a few, have been utilized for cancer vaccination strategies. Several factors such as size, shape, surface charge, route of administration, time in circulation, etc., of these nano-constructs determines the efficacy of the loaded immunological agents (vaccines). Cancer malignancies differ widely from each other in tumor antigen type and tumor microenvironment, which includes tumor resident and infiltrating immune cells. They are highly heterogenous within the same type of cancer (immune "hot" or "cold" tumors). For this reason, one-for-all design in the nanoparticle development to positively trigger immunogenicity will not work effectively for all types of cancer. A precise engineering of these systems by taking the tumor microenvironment and its immune status into consideration is of utmost importance. Engineering of nanoparticle design parameters will bring out a stable functional nanoplatform for cancer vaccine delivery. In this Special Issue, original research articles and reviews are welcome.

Guest Editors

Dr. Kondareddy Cherukula
Dr. Preethi Bala Balakrishnan
Dr. Santhosh Kalash Rajendrakumar

Deadline for manuscript submissions

closed (10 August 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/115953

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI